HONG KONG/LONDON (Reuters Breakingviews) – Corona Capital is a day by day column up to date all through the day by Breakingviews columnists around the globe with brief, sharp pandemic-related insights.
– Vaccine funding
ON THE MEND. Vietnam’s economic system eked out 0.36% progress within the second quarter in comparison with the identical interval a 12 months earlier, a uncommon vivid spot in Asia, the place most international locations are forecast to shrink this 12 months. Hanoi has efficiently contained Covid-19, and whereas tourism is unlikely to get better anytime quickly – weighing on a tenth of GDP – there are inexperienced shoots: industrial output for June was up an encouraging 7%. Factories are open and international firms are energetic as soon as extra, particularly as they appear to diversify provide chains away from China. U.S. chipmaker Qualcomm, for instance, unveiled plans final week to open its first analysis and improvement facility within the nation. Vietnam is bouncing again. (By Robyn Mak)
BOOSTER SHOT. Temasek is hoping for further bang from its vaccine funding buck. The Singapore sovereign wealth fund, together with different buyers, ploughed $250 million into BioNTech, a German agency engaged on limitations to Covid-19. Not like different builders, BioNTech is engaged on 4 vaccines concurrently, an strategy it reckons offers it an edge. Its medicine goal a particular protein discovered within the lethal virus and activate antibodies when vaccinated persons are contaminated.
Temasek’s timing seems sensible. BioNTech is making ready to launch knowledge from a human trial in Germany and America that began in April. If the outcomes show promising, different buyers might wish to pile in. The $14 billion Nasdaq-listed group’s shares are already up 54% because the starting of the 12 months. $24 billion rival Moderna, which has launched part one knowledge utilizing comparable know-how, has seen its share value treble over the identical interval. (By Aimee Donnellan)
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.